Strides Pharma Inc Pharmaceutical Import Profile — United States (DGFT 2022–2026)

Name: Strides Pharma Inc Pharmaceutical Import Records from India — 12 Products, $47.3M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Strides Pharma Inc — Pharmaceutical Importer Profile (2026) | 12 Products, $47.3M Trade | TransData Nexus

Strides Pharma Inc

Pharmaceutical Importer · United States · Vitamins & Supplements Focus · $47.3M Total Trade · DGFT Verified

Strides Pharma Inc is a pharmaceutical importer based in United States with a total trade value of $47.3M across 12 products in 9 therapeutic categories. Based on 946 verified import shipments from Indian Customs (DGFT) records, Strides Pharma Inc is the #1 buyer in 5 products including Prednisone, Hydrocortisone, Acarbose. Strides Pharma Inc sources from 4 verified Indian suppliers, with Strides Pharma Science Limited accounting for 88.0% of imports.

Strides Pharma Inc — Import Portfolio & Supplier Network

Strides Pharma Inc import network — 12 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Strides Pharma Inc?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Strides Pharma Science Limited	$75.6M	2,052	88.0%
Strides Alathur Private Limited	$6.1M	147	7.1%
Vivimed Life Sciences Private Limited	$4.0M

What Formulations Does Strides Pharma Inc Import?

Formulation	Value	Ships
Peg 3350 sodium bicarbonate sodium	$3.1M	108
Oseltamivir phosphate capsules USP	$1.1M	21
Peg 3350 and electrolytes for oral	$984.8K	38
Peg 3350, sodium bicarbonate, sodium	$795.3K	25
Mycophenolate mofetil tablets USP (500MG	$650.0K	13
Omega-3-acid ethyl esters capsules [1g][soft gelatin] Each soft gelatin capsulecontains 1g omega-3-acid ethyl ester	$600.0K	12
Mycophenolate mofetil tablets USP [500MG	$500.0K	10
Peg 3350, sodium bicarbonate, sodium chloride, potasium chloride for oral solution with lemon flavour 6,400.00x	$489.3K	14
Calcitriol capsules (0.25mcg)(soft	$438.9K	13
Calcitriol capsules (0.5mcg)(soft	$419.2K	12
Omega-3-acid ethyl esters capsules [1g][soft gelatin] Each soft gelatin capsulecontains 1g omega-3-acid ethyl ester	$400.0K	8
Peg 3350, sodium bicarbonate, sodium chloride, potasium chloride for oral solution with lemon flavour 6,400.00 x	$355.7K	10
Peg 3350, sodium bicarbonate, sodium chloride, potasium chloride for oral solution with lemon flavour 6,400.00x	$350.0K	9
Oseltamivir phosphate capsules USP	$350.0K	7
Benzonatate capsules USP (200MG)(soft	$335.7K	7

Strides Pharma Inc imports 1,496 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 12 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Iron	Vitamins & Supplements	$10.7M	214	1.2%	9
2	Prednisone	Respiratory	$8.4M	168	17.6%	1
3	Mycophenolate	Immunosuppressants	$6.8M	136	0.9%	2
4	Hydrocortisone	Corticosteroids	$5.2M	104	6.4%	1
5	Ibuprofen	Analgesics & Antipyretics	$3.8M	76	0.7%	10
6	Magnesium	Vitamins & Supplements	$3.0M	60	0.8%	11
7	Acarbose	Advanced Diabetes Medications	$2.4M	47	19.3%	1
8	Oseltamivir	Antivirals	$2.4M	47	1.3%	3
9	Omega	Nutritional Supplements	$2.3M	46	7.4%	1
10	Ketoconazole	Antifungals	$1.1M	23	2.0%	1
11	Tacrolimus	Immunosuppressants	$1.1M	22	0.5%	16
12	Theophylline	Respiratory	$150.0K	3	1.0%	15

Strides Pharma Inc imports 12 pharmaceutical products across 9 categories into United States totaling $47.3M. The company is the #1 buyer for 5 products: Prednisone, Hydrocortisone, Acarbose, Omega, Ketoconazole.

Strides Pharma Inc — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Strides Pharma Inc. is a U.S.-based pharmaceutical importer and distributor specializing in finished dosage formulations, including tablets, capsules, syrups, and injections. As the front-end subsidiary of Strides Pharma Science Limited, headquartered in Bengaluru, India, Strides Pharma Inc. serves as a pivotal link in delivering high-quality generic medicines to the U.S. market. The company re-entered the U.S. market in 2015, focusing on niche, low-volume, and low-competition products that require advanced manufacturing capabilities.

Headquartered at 200 Crossing Boulevard, Suite 110, Bridgewater, New Jersey, Strides Pharma Inc. operates with a clear vision of providing quality healthcare products across prescription, over-the-counter (OTC), and consumer health markets. The company's portfolio includes a diverse range of products, with a particular emphasis on modified-release formulations, soft-gel capsules, topicals, and liquids. This strategic focus enables Strides Pharma Inc. to address specific therapeutic needs and maintain a competitive edge in the U.S. pharmaceutical landscape.

2Distribution Network

Strides Pharma Inc. has established a robust distribution network within the United States to ensure efficient delivery of its pharmaceutical products. The company's primary distribution center is located at 200 Crossing Boulevard, Suite 110, Bridgewater, New Jersey, serving as a strategic hub for logistics and supply chain operations. Additionally, Strides Pharma Inc. operates a manufacturing facility at 1 Ram Ridge Road, Chestnut Ridge, New York, which received a U.S. Food and Drug Administration (FDA) Establishment Inspection Report (EIR) in February 2026, confirming compliance with current Good Manufacturing Practices (cGMP).

The company's logistics capabilities are designed to support a wide geographic coverage across the United States, ensuring timely and reliable delivery of products to healthcare providers, pharmacies, and other stakeholders. While specific details regarding additional warehouse locations and distribution centers are not publicly disclosed, Strides Pharma Inc.'s strategic positioning in key U.S. locations underscores its commitment to maintaining an efficient and responsive supply chain.

3Industry Role

In the United States pharmaceutical supply chain, Strides Pharma Inc. functions primarily as a pharmaceutical importer and distributor. The company focuses on sourcing finished pharmaceutical formulations from its parent company, Strides Pharma Science Limited, and other suppliers, and distributing these products to various stakeholders within the U.S. healthcare system. By leveraging its manufacturing capabilities and distribution network, Strides Pharma Inc. plays a crucial role in enhancing access to affordable and high-quality generic medicines in the U.S. market.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Strides Pharma Inc

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Strides Pharma Inc. demonstrates a significant concentration in its sourcing strategy, with a substantial portion of its imports originating from Strides Pharma Science Limited. According to TransData Nexus proprietary trade data, Strides Pharma Inc. imported $75.6 million worth of products from Strides Pharma Science Limited, accounting for 88.0% of its total imports. This strong reliance indicates a strategic choice to maintain a streamlined and integrated supply chain, ensuring consistent product quality and supply reliability.

The company's import data reveals a stable and enduring relationship with its primary supplier, as evidenced by the high volume of shipments and the dominance of Strides Pharma Science Limited in the supply chain. This concentration may offer operational efficiencies and cost advantages; however, it also exposes Strides Pharma Inc. to potential risks associated with over-reliance on a single supplier. Diversifying the supplier base could mitigate such risks and enhance supply chain resilience.

2Supply Chain Resilience

Strides Pharma Inc.'s supply chain resilience is closely tied to its sourcing strategy, which heavily depends on Strides Pharma Science Limited. While this concentrated approach ensures product consistency and quality, it also presents challenges in terms of supply chain flexibility and risk management. The company's import data indicates a limited number of unique suppliers, with only four verified Indian suppliers, suggesting a lack of diversification in sourcing.

Importing Pharmaceuticals into United States — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for United States

1Regulatory Authority & Framework

In the United States, the Food and Drug Administration (FDA) serves as the primary regulatory authority overseeing the importation, manufacturing, and distribution of pharmaceutical products. The FDA enforces regulations to ensure the safety, efficacy, and quality of drugs available in the U.S. market.

Key legislation governing pharmaceutical imports includes the Federal Food, Drug, and Cosmetic Act (FDCA), which provides the legal framework for the FDA's regulatory activities. Additionally, the Drug Enforcement Administration (DEA) regulates controlled substances, ensuring compliance with the Controlled Substances Act. For Indian generics, the FDA's Abbreviated New Drug Application (ANDA) process is the primary pathway for marketing authorization, allowing for the approval of generic drugs based on bioequivalence to existing branded products.

2Import Licensing & GMP

Import licensing requirements for pharmaceutical products entering the United States are stringent. All imported drugs must comply with FDA regulations, including obtaining an FDA Establishment Inspection Report (EIR) for manufacturing facilities, which confirms adherence to current Good Manufacturing Practices (cGMP). Strides Pharma Inc.'s manufacturing facility at Chestnut Ridge, New York, received an EIR in February 2026, indicating compliance with cGMP standards.

Strides Pharma Inc — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Strides Pharma Inc.'s product strategy focuses on niche, low-volume, and low-competition products that require advanced manufacturing capabilities. The company's emphasis on modified-release formulations, soft-gel capsules, topicals, and liquids aligns with market demand for specialized and differentiated pharmaceutical products. This strategic focus enables Strides Pharma Inc. to address specific therapeutic needs and maintain a competitive edge in the U.S. market.

2Sourcing Profile

Strides Pharma Inc.'s sourcing strategy is centered on obtaining finished pharmaceutical formulations from its parent company, Strides Pharma Science Limited, and other suppliers. The company imports a diverse range of products, including iron supplements, prednisone, mycophenolate, hydrocortisone, and ibuprofen, across various therapeutic categories. This approach allows Strides Pharma Inc. to offer a comprehensive portfolio of generic medicines to the U.S. market.

3Market Positioning

Based on its product mix, Strides Pharma Inc. serves multiple segments of the United States market, including retail pharmacies, hospitals, government tenders, and

Frequently Asked Questions — Strides Pharma Inc

What products does Strides Pharma Inc import from India?

Strides Pharma Inc imports 12 pharmaceutical products across 9 categories. Top imports: Iron ($10.7M), Prednisone ($8.4M), Mycophenolate ($6.8M), Hydrocortisone ($5.2M), Ibuprofen ($3.8M).

Who supplies pharmaceuticals to Strides Pharma Inc from India?

Strides Pharma Inc sources from 4 verified Indian suppliers. The primary supplier is Strides Pharma Science Limited (88.0% of imports, $75.6M).

What is Strides Pharma Inc's total pharmaceutical import value?

Strides Pharma Inc's total pharmaceutical import value from India is $47.3M, based on 946 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Strides Pharma Inc focus on?

Strides Pharma Inc imports across 9 categories. The largest: Vitamins & Supplements (29.0%), Respiratory (18.1%), Immunosuppressants (16.7%).

Get Full Strides Pharma Inc Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.